Canagliflozin-induced diabetic ketoacidosis: Case report and review of the literature

Journal of Investigative Medicine High Impact Case Reports

Volumn 4, Issue 3, 2016, Pages

  Turner, Jessica ^a   Begum, Tahmina ^a   Smalligan, Roger D ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Canagliflozin; Diabetic ketoacidosis; SGLT 2 inhibitors

Indexed keywords

CANAGLIFLOZIN;

ADULT; BLOOD PRESSURE MONITORING; BREATHING RATE; CASE REPORT; CHLORIDE BLOOD LEVEL; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIABETIC KETOACIDOSIS; FEMALE; FLUID RESUSCITATION; GLUCOSE BLOOD LEVEL; HEART RATE; HOSPITAL ADMISSION; HUMAN; METABOLIC ACIDOSIS; MIDDLE AGED; OXYGEN SATURATION; PH; POLYDIPSIA; POLYURIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SODIUM BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

EID: 85016258517     PISSN: None     EISSN: 23247096     Source Type: Journal    
DOI: 10.1177/2324709616663231     Document Type: Review

References (15)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services; 2014.
2. Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013;53:601-610.
3. FDA Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed July 15, 2015.
4. Gelaye A, Haidar A, Kassab C, Kazmi S, Sinha P. Severe ketoacidosis associated with canagliflozin (Invokana): a safety concern. Case Rep Crit Care. 2016;2016:1656182.
5. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care. 2016;39:532-538.
6. Syed SH, Gosavi S, Shami W, et al. A review of sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin and empagliflozin. Cardiovasc Hematol Agents Med Chem. 2015;13:105-112.
7. Hine J, Paterson H, Abrol E, Russell-Jones D, Herring R. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol. 2015;3:503-504.
8. Storgaard H, Bagger JI, Knop FK, Vilsbøll T, Rungby J. Diabetic ketoacidosis in a patient with type 2 diabetes after initiation of sodium-glucose cotransporter 2 inhibitor treatment. Basic Clin Pharmacol Toxicol. 2016;118:168-170.
9. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016;7:135-138.
10. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig. 2015;6: 587-590.
11. FDA Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Accessed April 26, 2016.
12. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508.
13. Peters A, Buschur E, Buse J, Cohan P, Diner J, Hirsch I. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687-1693.
14. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680-1686.
15. Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22:753-762.